Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06582628 | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)(TEAM PC) | recruiting | Phase 2 | 78 | Fundacion OncosurNETWORK | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC(ANZadapt) | recruiting | Phase 2 | 168 | Leiden University Medical CenterOTHER | 2 |
| Nov 26, 2024 |
| clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06617481 | PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence | recruiting | Phase 2 | 30 | AdventHealthOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06655259 | Combination of TURP and Standard Systemic Therapy for MPCa(CTUSMEP01) | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05558007 | Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | recruiting | Phase 2 | 72 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06636682 | FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | recruiting | Phase 2 | 100 | Cellvax Therapeutics IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06575257 | Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer | recruiting | Phase 2 | 80 | Xijing HospitalOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06387056 | Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)(SEGNO) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06305832 | Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 102 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06259123 | Neoadjuvant PSMA-RLT in Oligometastatic PCa | recruiting | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05851547 | Dose Escalation For INtraprostatic LEsions(DEFINE) | recruiting | Phase 2 | 54 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04654338 | 2 Ablative RadioTherapy Treatments for Prostate Cancer(EARTH) | recruiting | Phase 2 / Phase 3 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05753566 | Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 96 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05557604 | Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer(STUNNIN) | recruiting | Phase 2 | 146 | Regina Elena Cancer InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05406999 | Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 900 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03753243 | Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer | recruiting | Phase 2 | 32 | Mark Garzotto, MDFED | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05010343 | Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer | recruiting | Phase 2 | 140 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04700332 | PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer | recruiting | Phase 2 | 184 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT03541928 | Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery | recruiting | Phase 2 | 60 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03294889 | ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer | recruiting | Phase 1 / Phase 2 | 45 | University Hospital, GenevaOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT04212715 | Prostate SABR With Intra-Prostatic SABR Boost | recruiting | Phase 2 | 30 | King Saud UniversityOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03392233 | Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors | recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02391051 | Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial(FOKAL-BT) | recruiting | Phase 2 | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01913106 | HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | recruiting | Phase 1 / Phase 2 | 25 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 1, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2024source: clinicaltrials